Human immunodeficiency virus type 1 (HIV-1) protease has been continuously evolving and developing resistance to all of the protease inhibitors. This requires the development of new inhibitors that bind to the protease in a novel fashion. Most of the inhibitors that are on the market are peptidomimetics, where a conserved water molecule mediates hydrogen bonding interactions between the inhibitors and the flaps of the protease. Recently a new class of inhibitors, lysine sulfonamides, was developed to combat the resistant variants of HIV protease. Here we report the crystal structure of a lysine sulfonamide. This inhibitor binds to the active site of HIV-1 protease in a novel manner, displacing the conserved water and making extensive hydrog...
The HIV-1 protease is essential for replication of in-fective virus HIV, and therefore is an attract...
Molecular recognition is central to biology and ranges from highly selective to broadly promiscuous....
HIV affects the lives of about 37 million patients worldwideincluding around one million Americans. ...
AbstractBackground: The HIV protease is essential for the life cycle of the virus and is an importan...
Ten years ago, the first protease inhibitor targeting the human immunodeficiency virus (HIV) was app...
The homodimeric HIV-1 protease is the target of some of the most effective antiviral AIDS therapy, a...
Motivation: HIV-1 protease is a key drug target due to its role in the life cycle of the HIV-1 virus...
Human immunodeficiency virus HIV protease is a well established drug target in HIV chemotherapy. H...
Human immunodeficiency virus HIV protease is a well established drug target in HIV chemotherapy. H...
It is known that HIV-1 protease is an important target for design of antiviral compounds in the trea...
It is known that HIV-1 protease is an important target for design of antiviral compounds in the trea...
BACKGROUND: It is known that HIV-1 protease is an important target for design of antiviral compounds...
Being the HIV-1 Protease (HIV-1-PR) an essential enzyme in the viral life cycle, its inhibition can ...
Antiviral inhibitors of HIV-1 protease are a notable success of structure-based drug design and have...
AbstractBackground: The HIV protease is essential for the life cycle of the virus and is an importan...
The HIV-1 protease is essential for replication of in-fective virus HIV, and therefore is an attract...
Molecular recognition is central to biology and ranges from highly selective to broadly promiscuous....
HIV affects the lives of about 37 million patients worldwideincluding around one million Americans. ...
AbstractBackground: The HIV protease is essential for the life cycle of the virus and is an importan...
Ten years ago, the first protease inhibitor targeting the human immunodeficiency virus (HIV) was app...
The homodimeric HIV-1 protease is the target of some of the most effective antiviral AIDS therapy, a...
Motivation: HIV-1 protease is a key drug target due to its role in the life cycle of the HIV-1 virus...
Human immunodeficiency virus HIV protease is a well established drug target in HIV chemotherapy. H...
Human immunodeficiency virus HIV protease is a well established drug target in HIV chemotherapy. H...
It is known that HIV-1 protease is an important target for design of antiviral compounds in the trea...
It is known that HIV-1 protease is an important target for design of antiviral compounds in the trea...
BACKGROUND: It is known that HIV-1 protease is an important target for design of antiviral compounds...
Being the HIV-1 Protease (HIV-1-PR) an essential enzyme in the viral life cycle, its inhibition can ...
Antiviral inhibitors of HIV-1 protease are a notable success of structure-based drug design and have...
AbstractBackground: The HIV protease is essential for the life cycle of the virus and is an importan...
The HIV-1 protease is essential for replication of in-fective virus HIV, and therefore is an attract...
Molecular recognition is central to biology and ranges from highly selective to broadly promiscuous....
HIV affects the lives of about 37 million patients worldwideincluding around one million Americans. ...